Aviva PLC Has $19.08 Million Position in Insulet Co. (NASDAQ:PODD)

Aviva PLC cut its holdings in shares of Insulet Co. (NASDAQ:PODD – Get Rating) by 81.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 9,360 shares of the medical instruments supplier’s stock after selling 40,489 shares during the quarter. Aviva PLC’s holdings in Insulet were worth $19,079,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the business. Aigen Investment Management LP acquired a new position in shares of Insulet during the 4th quarter worth approximately $685,000. Mitsubishi UFJ Trust & Banking Corp grew its holdings in Insulet by 4.6% in the 4th quarter. Mitsubishi UFJ Trust & Banking Corp now owns 39,358 shares of the medical instruments supplier’s stock valued at $11,587,000 after buying an additional 1,719 shares in the last quarter. Blair William & Co. IL grew its holdings in Insulet by 0.4% in the 4th quarter. Blair William & Co. IL now owns 324,947 shares of the medical instruments supplier’s stock valued at $95,661,000 after buying an additional 1,150 shares in the last quarter. Vanguard Personalized Indexing Management LLC grew its holdings in Insulet by 14.2% in the 4th quarter. Vanguard Personalized Indexing Management LLC now owns 4,726 shares of the medical instruments supplier’s stock valued at $1,391,000 after buying an additional 587 shares in the last quarter. Finally, Tredje AP fonden grew its holdings in Insulet by 2.5% in the 4th quarter. Tredje AP fonden now owns 14,030 shares of the medical instruments supplier’s stock valued at $4,130,000 after buying an additional 347 shares in the last quarter.

Insider Buying and Selling at Insulet

In other Insulet news, CFO Wayde D. Mcmillan sold 1,255 shares of the stock in a transaction dated Monday, April 3rd. The stock was sold at an average price of $318.31, for a total value of $399,479.05. Following the completion of the transaction, the chief financial officer now directly owns 22,865 shares in the company, valued at $7,278,158.15. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other Insulet news, CFO Wayde D. Mcmillan sold 1,255 shares of the stock in a transaction dated Monday, April 3rd. The stock was sold at an average price of $318.31, for a total value of $399,479.05. Following the completion of the transaction, the chief financial officer now directly owns 22,865 shares in the company, valued at $7,278,158.15. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Charles Alpuche sold 4,000 shares of the stock in a transaction dated Tuesday, February 28th. The shares were sold at an average price of $278.82, for a total value of $1,115,280.00. Following the completion of the transaction, the insider now owns 45,584 shares of the company’s stock, valued at $12,709,730.88. The disclosure for this sale can be found here. Over the last three months, insiders sold 32,656 shares of company stock worth $9,819,174. 0.90% of the stock is currently owned by insiders.

Insulet Price Performance

Shares of PODD stock opened at $277.05 on Friday. The company has a quick ratio of 2.46, a current ratio of 3.47 and a debt-to-equity ratio of 2.72. Insulet Co. has a twelve month low of $192.33 and a twelve month high of $335.91. The company has a market cap of $19.31 billion, a P/E ratio of 251.07, a P/E/G ratio of 6.10 and a beta of 0.80. The business has a fifty day simple moving average of $315.74 and a 200 day simple moving average of $302.26.

Insulet (NASDAQ:PODD – Get Rating) last announced its quarterly earnings data on Thursday, May 4th. The medical instruments supplier reported $0.23 earnings per share for the quarter, topping the consensus estimate of $0.09 by $0.14. Insulet had a return on equity of 17.29% and a net margin of 0.04%. The business had revenue of $358.10 million during the quarter, compared to the consensus estimate of $330.21 million. During the same period in the prior year, the company earned $0.40 EPS. Insulet’s revenue for the quarter was up 21.2% on a year-over-year basis. On average, sell-side analysts forecast that Insulet Co. will post 1.37 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

PODD has been the topic of a number of research reports. Morgan Stanley upped their price objective on Insulet from $320.00 to $325.00 and gave the company an “equal weight” rating in a report on Friday, February 24th. Piper Sandler upped their price objective on Insulet from $340.00 to $360.00 in a report on Friday, May 5th. Barclays upped their price objective on Insulet from $292.00 to $329.00 in a report on Monday, May 8th. BTIG Research increased their target price on Insulet from $340.00 to $350.00 and gave the stock a “buy” rating in a report on Monday, April 17th. Finally, Wolfe Research initiated coverage on Insulet in a report on Thursday, January 26th. They set a “peer perform” rating on the stock. Eight research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $330.00.

Insulet Company Profile

(Get Rating)

Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System, as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals.